KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Investing Activities (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Cash from Investing Activities data on record, last reported at $96.2 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 87.41% year-over-year to $96.2 million; the TTM value through Dec 2025 reached $69.6 million, down 90.78%, while the annual FY2025 figure was $69.6 million, 90.78% down from the prior year.
  • Cash from Investing Activities reached $96.2 million in Q4 2025 per SRPT's latest filing, down from $232.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $764.1 million in Q4 2024 and bottomed at -$785.8 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is $5.4 million, with a median of $15.8 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: tumbled 1201.37% in 2023, then soared 1651.49% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$2.6 million in 2021, then skyrocketed by 480.13% to $9.8 million in 2022, then plummeted by 756.98% to -$64.4 million in 2023, then soared by 1287.29% to $764.1 million in 2024, then tumbled by 87.41% to $96.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $96.2 million in Q4 2025, $232.4 million in Q3 2025, and $32.2 million in Q2 2025.